Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of São Paulo
• Treatments: Ganciclovir; Ganciclovir triphosphate; Lubricant Eye Drops

Criteria

Inclusion Criteria:

• onset of symptoms for five days or less

• eighteen years old or more

• not pregnant or breastfeeding

• be able to understand and sign the consent term

Exclusion Criteria:

• use of antibiotic or corticoid 30 days before

• monocular vision

• keratopathy or other ocular diseases